Senior Director, Program Management Systems and Infrastructures at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Experience leading enterprise-wide Program Management (PM) Systems and Infrastructure ecosystems
Expertise in key platforms: ePlan (Planisware), Microsoft Project/Planner, and Global Program Team (GPT) collaborative workspaces (e.g., SharePoint, Teams, OneNote)
Ability to ensure system interoperability, data quality, data governance, and readiness for business processes (e.g., month-end close, financial reviews, portfolio processes)
Strategic vision for AI integration, automation, analytics, and innovation in PM aligned with PPM Strategic Vision
Partnership experience with R&D, PPM, and BI&T leadership
Capability to establish and lead high-performing teams driving cross-functional integration

Responsibilities

Develop, implement, and sustain an enterprise-wide PM Systems and Infrastructure ecosystem for operational efficiency, strategic visibility, and data-driven decision-making
Lead the vision and execution of the Enterprise Program Management (EPM) environment, supporting program managers and PM Leadership with integrated, scalable tools and processes
Oversee ePlan (Planisware) as system owner: simplify/maintain environment, enable scheduling, timeline/critical path visibility, scenario planning, and resource forecasting; partner with R&D functions for data sharing
Oversee Microsoft Project/Planner for bottom-up planning of near-term deliverables and GPT collaborative workspaces as secure repositories enhancing transparency
Establish and lead the PM Systems & Infrastructures function, setting strategic vision for unified EPM ecosystem
Define and drive multi-year roadmap for enterprise planning systems, aligned with PPM strategy, R&D objectives, and business needs
Champion innovation via AI, automation, and analytics for proactive portfolio management
Set standards for enterprise data integrity and design future-forward digital solutions supporting scientific, operational, and business objectives

Skills

Program Management

Planisware

ePlan

Microsoft Project

Microsoft Planner

Data Governance

Portfolio Management

Enterprise PM Systems

System Interoperability

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free